THERAPY DOSSIER · th-bbf0d0c029a1

Caspase-2 small interfering RNA (siCASP2)

Biologic · Caspase-2 small interfering RNA (siCASP2); RNAi therapeutic.

Evidence & regulatory context

Mechanism: Caspase-2 small interfering RNA (siCASP2); RNAi therapeutic.
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30193318 ↗2018Mixed findings

Caspase-2 Mediates Site-Specific Retinal Ganglion Cell Death After Blunt Ocular Injury.

RatOtherLister-hoodedFemaleIntravitreal injection

Model: Bilateral ballistic closed globe blunt ocular trauma

Caspase-2 knockdown protected retinal ganglion cells around but not within the centre of the injury site and increased the amplitude of the photopic negative response at two weeks. It gave no protection to photoreceptors, indicating photoreceptor degeneration in this model is not caspase-2 mediated.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…